Anagliptin ameliorates albuminuria and urinary liver-type fatty acid-binding protein excretion in patients with type 2 diabetes with nephropathy in a glucose-lowering-independent manner

Anagliptin ameliorates albuminuria and urinary liver-type fatty acid-binding protein excretion in patients with type 2 diabetes with nephropathy in a glucose-lowering-independent manner

Objective The objective of this study is to elucidate the effect of anagliptin on glucose/lipid metabolism and renoprotection in patients with type 2 diabetic nephropathy.Methods Twenty-five patients with type 2 diabetic nephropathy received anagliptin 200 mg/day for 24 weeks, and 20 patients who we...

Full description

Saved in:
Bibliographic Details
Main Authors: Daisuke Koya, Mizue Fujii, Munehiro Kitada, Shin-ichi Tsuda, Kazunori Konishi, Ai Takeda-Watanabe, Keizo Kanasaki, Makoto Nishizawa, Atsushi Nakagawa
Format: Article
Language:English
Published: BMJ Publishing Group 2017-07-01
Series:BMJ Open Diabetes Research & Care
Online Access:https://drc.bmj.com/content/5/1/e000391.full
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items